Pharmacology - Oct 22
Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US
Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US
Pharmacology - Oct 21
Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma
Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma
« BACK
Social Sciences - Law - 26.04.2016 
The law enforcement system is ill-prepared for dying prisoners
In Switzerland, an increasing number of offenders are aging and dying in prison. Penal institutions need to better adjust to this situation, and uniform rules are needed to ensure a dignified end of life in prison.
Social Sciences - Law - 28.10.2008
Law
Results 1 - 2 of 2.
In Switzerland, an increasing number of offenders are aging and dying in prison. Penal institutions need to better adjust to this situation, and uniform rules are needed to ensure a dignified end of life in prison.
Ist das neue Gesetz gegen häusliche Gewalt effizient?
Mit den neuen Bestimmungen des Schweizerischen Strafgesetzbuches zur Strafverfolgung in der Ehe und in der Partnerschaft soll häusliche Gewalt besser bekämpft werden.
Mit den neuen Bestimmungen des Schweizerischen Strafgesetzbuches zur Strafverfolgung in der Ehe und in der Partnerschaft soll häusliche Gewalt besser bekämpft werden.
Pharmacology - Oct 22
Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US
Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US
Pharmacology - Oct 21
Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma
Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma